139 related articles for article (PubMed ID: 38400801)
1. Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.
Akita T; Ariyasu R; Kakuto S; Miyadera K; Kiritani A; Tsugitomi R; Amino Y; Uchibori K; Kitazono S; Yanagitani N; Tasaka S; Nishio M
Thorac Cancer; 2024 Apr; 15(10):788-796. PubMed ID: 38400801
[TBL] [Abstract][Full Text] [Related]
2. [Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKI in advanced non-small cell lung cancer harboring EGFR mutations].
Jin B; Zhang Y; Zhang X; Li R; Lou Y; Niu Y; Huang A; Han B
Zhonghua Yi Xue Za Zhi; 2014 Aug; 94(30):2327-31. PubMed ID: 25399971
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers.
Zhu K; Chen L; He C; Lang Y; Kong X; Qu C; Xu S
Dis Markers; 2020; 2020():6430459. PubMed ID: 32089756
[TBL] [Abstract][Full Text] [Related]
4. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
Chen H; Yang X; Liu H; Ma K; Zhong J; Dong Z; Zhuo M; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):589-597. PubMed ID: 28935011
[TBL] [Abstract][Full Text] [Related]
5. [Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].
Wang Q; Zheng H; Hu F; Zhang H; Hu Y; Li J; Zhang T; Liu Z; Lu B; Hu A; Li B
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):550-8. PubMed ID: 27561807
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
7. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
Jiang R; Wang X; Li K
Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
[TBL] [Abstract][Full Text] [Related]
9. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types].
Gao J; Zhang L; Peng K; Sun H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jun; 42(6):886-891. PubMed ID: 35790439
[TBL] [Abstract][Full Text] [Related]
11. Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy.
Chen Z; Liu L; Zhu F; Cai X; Zhao Y; Liang P; Ou L; Zhong R; Yu Z; Li C; Li J; Xiong S; Feng Y; Cheng B; Liang H; Xie Z; Liang W; He J
Cancer Med; 2022 Aug; 11(16):3115-3125. PubMed ID: 35543090
[TBL] [Abstract][Full Text] [Related]
12. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
Wang WT; Li Y; Ma J; Chen XB; Qin JJ
Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
[TBL] [Abstract][Full Text] [Related]
13. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
14. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
15. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
16. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
17. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients].
Duan X; Cui Y; Gong M; Tian F; Shi G; Wu B; Liu M; Guo J; Kong Y
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):358-64. PubMed ID: 26104892
[TBL] [Abstract][Full Text] [Related]
18. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]